Table of Contents

The 30-Day Migraine Diary: How Tracking Headache Frequency Helps Determine BOTOX Eligibility

Maria, a 42-year-old middle-school teacher in El Paso, sat at her kitchen table on a quiet Sunday evening and opened a simple notebook. For years, she had described her problem as “four severe migraines a month.” She missed a couple of days of work, rested in a dark room, and then pushed through the rest of the calendar. When her nurse practitioner asked her to keep a 30-day headache diary, Maria expected the same four entries. What she wrote down surprised her.

By the end of the month, the notebook showed 16 separate days with head pain. Only four of those days met the full picture of a classic migraine attack—throbbing on one side, nausea, and light sensitivity that forced her to stop teaching. The other twelve days carried milder but still disruptive pressure, residual fog, or shorter episodes that still kept her from grading papers after school or sleeping through the night. Those extra days mattered.

A carefully kept headache diary turns a vague memory into usable information. It helps clinicians decide whether someone meets the criteria for chronic migraine and, in turn, whether FDA-approved BOTOX (onabotulinumtoxinA) may be appropriate. It also shows patients and their care team what is changing over time so they can adjust treatment with clear eyes.

What Counts as a Headache Day Versus a Migraine Attack

Chronic migraine, as defined by the International Classification of Headache Disorders (ICHD-3), means headache on 15 or more days per month for more than three months, with migraine features present on at least eight of those days, in a person who already has a history of migraine (International Headache Society, 2018). FDA labeling for BOTOX follows a similar threshold: the treatment is indicated for preventing headaches in adults with chronic migraine who experience 15 or more headache days per month, with headaches lasting four hours or longer (AbbVie, 2026). Safety and effectiveness have not been established for people who have 14 or fewer headache days per month.

Four full migraine attacks can feel devastating, yet they may still fall short of the chronic-migraine threshold. Sixteen headache days cross that line even if only a portion of them carry the classic migraine features of unilateral location, pulsating quality, moderate-to-severe intensity, nausea, or sensitivity to light or sound. Patients frequently undercount the milder days. The diary closes that gap.

How Maria Tracked the Details That Matter

Maria’s notebook used a simple daily template. Each evening she recorded:

Whether any head pain occurred that day (yes or no).
Duration in hours.
Location and quality (one side or both, throbbing or steady pressure).
Associated features (nausea, light or sound sensitivity, visual changes, and neck tightness).
Medication taken and whether it helped.
Possible triggers (poor sleep, skipped meals, classroom stress, weather, screen time).
Disability impact (classes missed, grading delayed, early bedtime, irritability with family).

Week 1 showed three migraine-feature days and four milder headache days. Week 2 added two more migraine-feature days after a short night of sleep. By week 4, the totals stood at 16 headache days and 8 days that clearly met migraine criteria. Sleep disruption appeared on 11 of the headache days. Acute medication was used on 9 of those days. The pattern was no longer “four severe attacks.” It was a near-daily burden that met guideline thresholds for chronic migraine and for consideration of preventive therapy, including BOTOX when other factors aligned.

Why the Diary Supports Diagnosis and Treatment Monitoring

Clinicians need more than a patient’s best recollection. The diary provides the day-by-day count required by ICHD-3 and by BOTOX labeling. It also reveals medication-overuse patterns, sleep-related triggers, and functional losses that pure pain scores can miss. After treatment begins, the same diary shows whether headache days are dropping, whether residual pain is shortening, and whether disability is easing. Studies of preventive therapies, including the PREEMPT trials that supported BOTOX approval, relied on headache diaries to measure reductions in headache days (Dodick et al., 2010).

Patients who track consistently gain practical advantages.

They see which lifestyle factors most reliably precede a bad day.
They can share an objective record with every member of their care team.
They become active participants rather than passive recipients of care.

Bioethical Pillars in Everyday Tracking

Beneficence appears when the diary guides care that addresses the actual frequency and functional cost of the headaches. Accurate counts allow the team to match the right preventive approach—whether BOTOX, other pharmacologic options, chiropractic care for coexisting neck tension, acupuncture, sleep coaching, or nutritional support—to the patient’s real pattern. Root-cause work becomes possible once the numbers are clear.

Non-maleficence is protected when the diary prevents both undertreatment and over-treatment. A person with only four migraine days may still need prevention, yet BOTOX is not indicated until the 15-day threshold is met. The record keeps decisions within evidence-based boundaries and reduces the chance that someone starts a therapy for which safety and effectiveness have not been shown.

Autonomy is strengthened when the patient owns the data. Maria could see her pattern, ask informed questions, and decide, with education, whether to pursue BOTOX or first intensify lifestyle and non-pharmacologic measures. The diary belongs to the patient; the clinic supplies the framework and interpretation.

What Makes This Clinic Distinct in El Paso

Injury Medical Chiropractic and Functional Medicine Clinic is the only practice in El Paso that combines a board-certified internal medicine physician as medical director with a dual-licensed chiropractor and family nurse practitioner who specializes in soft-tissue injury. Dr. Maria Guadalupe Cardenas, MD, provides medical direction, advanced laboratory interpretation, and internal medicine oversight for complex metabolic and inflammatory contributors. Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, evaluates cervical and soft-tissue drivers of headache, performs functional testing, and coordinates non-invasive options such as chiropractic adjustments, neurofunctional acupuncture, and electroacupuncture. Together, they review the same headache diary, correlating frequency counts with cervical range of motion, sleep quality, and inflammatory markers when indicated. No other clinic in the city offers this integrated medical-director-plus-soft-tissue-NP model under one roof for patients who need both precise diagnostic tracking and multidisciplinary recovery support.

Practical Steps Patients Can Start Tonight

Keep the diary for a full 30 days before the next visit. Note every day, even the positive ones. Bring the notebook or a printed copy to the appointment. Discuss the totals with the care team so they can place the record alongside clinical examination findings. Continue the diary after any new treatment begins; the comparison is what shows whether headache days and disability are truly improving.

For readers who want deeper background on BOTOX criteria, chronic-migraine diagnosis, and integrated care pathways, the clinic’s 2026 clinical guide on FDA-approved BOTOX for chronic migraine and the complete integrated migraine treatment guide on dralexjimenez.com provide clear, evidence-based explanations written for patients and clinicians alike. Additional practical pages on migraine treatment and headache management appear throughout the site and can be reviewed before an appointment.

A 30-day diary does not diagnose or prescribe on its own. It gives patients and their clinicians the shared, accurate picture needed to decide whether BOTOX is appropriate and whether the chosen plan is working. For Maria, the notebook changed the conversation from “four bad days” to a documented chronic pattern that could finally be addressed with precision.

References

AbbVie Inc. (2024). BOTOX (onabotulinumtoxinA) for injection, for intramuscular use [Prescribing information]. www.rxabbvie.com/pdf/botox_pi.pdf

Dodick, D. W., Turkel, C. C., DeGryse, R. E., Aurora, S. K., Silberstein, S. D., Lipton, R. B., Diener, H.-C., & Brin, M. F. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia, 30(7), 793–803. doi.org/10.1177/0333102410364676

Aurora, S. K., Dodick, D. W., Turkel, C. C., DeGryse, R. E., Silberstein, S. D., Lipton, R. B., Diener, H.-C., & Brin, M. F. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia, 30(7), 804–814. doi.org/10.1177/0333102410364677

Headache Classification Committee of the International Headache Society (IHS). (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1–211. doi.org/10.1177/0333102417738202